Erythropoietin Drugs Market Evolution 2023: Recent Developments in the Market with Key Players Announcements

Introduction:

As per the report published by Allied Market Research, the global Erythropoietin Drugs Market was pegged at $9.24 billion in 2020, and is estimated to reach $14.41 billion by 2028, growing at a CAGR of 5.7% from 2021 to 2028. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.

Key Takeaways:

• Epoetin-alfa segment would continue to maintain the lead over the forecast period.
• Kidney Disorders Segment is projected as one of the most lucrative segment.
• Asia-pacific is a promising market for growth of erythropoietin and majority of originator companies for erythropoietin are focusing on the Asia-pacific market.

Request Sample Copy of the Report: 

https://www.alliedmarketresearch.com/request-sample/59

Market Segmentation:

By Drug Class:

• Biologics: This segment dominates the market, encompassing recombinant human erythropoietin (rHuEPO) products like Epoetin alfa, darbepoetin alfa, and epoetin beta. These are typically injectable and used for anemia treatment in various settings like chronic kidney disease (CKD), cancer therapy-induced anemia, and pre-operative anemia.
• Biosimilars: As patents for certain rHuEPO products expire, biosimilars are gaining traction due to their lower cost and comparable efficacy. This segment is expected to see significant growth in the coming years.

By Product:

• First-generation formulations: These are the traditional rHuEPO products like Epoetin alfa and beta, often administered frequently due to their shorter half-life.
• Second-generation formulations: These newer rHuEPO products like darbepoetin alfa offer longer half-lives and require less frequent injections, improving patient convenience and compliance.
• Other formulations: This category includes less common options like pegolylated epoetin alfa, which further extends the half-life and reduces injection frequency.

By Application:

• Renal diseases: This is the largest application segment, driven by the high prevalence of anemia in CKD patients and the long-term treatment requirement.
• Cancer therapy-induced anemia: Chemotherapy and other cancer treatments can suppress red blood cell production, leading to anemia. Erythropoietin drugs play a vital role in managing this side effect.
• Other applications: This includes pre-operative anemia management, HIV-associated anemia, and certain rare blood disorders.

By End User:

• Hospitals: These are major consumers due to the high volume of patients requiring erythropoietin therapy, particularly for CKD and cancer treatment.
• Dialysis centers: These cater to CKD patients on dialysis, a significant population needing regular erythropoietin injections.
• Clinics and healthcare providers: Smaller clinics and individual healthcare providers also utilize erythropoietin drugs for various indications.

Regional Growth Dynamics:

Based on the region, the global Erythropoietin Drugs Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The market across North America held the largest share in 2020, accounting for more than one-third of the market. However, the market across Asia-Pacific is projected to register the highest CAGR of 7.8% from 2021 to 2028.

Request for Customization : https://www.alliedmarketresearch.com/request-for-customization/59

Competitive Landscape:

• Johnson & Johnson
• Amgen Inc.
• Roche
• Hospira Inc.
• Biocon
• LG Life Sciences Ltd.
• Teva Pharmaceutical Industries Ltd.
• Intas Pharmaceuticals
• Ranbaxy Laboratories Ltd.
• Celltrion, Inc.

Key Benefits for Stakeholders:

• The study provides an in-depth analysis of the global erythropoietin drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the erythropoietin drugs market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing erythropoietin drugs market opportunities.
• Extensive analysis of the key segments of the erythropoietin drugs industry helps to understand the application and products of erythropoietin used across the globe.

Buy this Premium Research Report: 

https://www.alliedmarketresearch.com/purchase-enquiry/59

Key Questions Answered in the Intelligent Study

What is the market size and growth rate of the global and regional market by various segments?
What is the market size and growth rate of the market for selective countries?
Which region or sub-segment is expected to drive the market in the forecast period?
What Factors are estimated to drive and restrain the market growth?
What are the key technological and market trends shaping the market?
What are the key opportunities in the market?
What are the key companies operating in the market?
Which company accounted for the highest market share?

Why Choose Allied Market Research?

Industries’ Best Analysts
Exclusive Product Offerings
Customer Research Services
Dynamics Research Methodology
Comprehensive Reports
Latest Technological Advancements
Value Chain Analysis
Future Market Opportunities
Market Growth Dynamics
Quality Assurance
Post-sales Support
Continuous Report Update

Market Dynamics and Transformations

Economic Downturn Analysis: Impact of Recession in 2023
Pandemic’s Influence: Impact of Covid-19 Pandemic
Market Evolution: Recent Developments in the Market with Key Players Announcements

Similar Reports:

Exosome Diagnostic and Therapeutic Market: 

https://www.alliedmarketresearch.com/exosome-diagnostic-and-therapeutic-market

Bone Grafts and Substitutes Market:

https://www.alliedmarketresearch.com/bone-graft-substitutes-market